Form 4: BioLife Solutions CFO Sells Shares Under 10b5-1 Trading Plan

BioLife Solutions' Chief Financial Officer, Troy Wichterman, sold 987 shares of common stock at $27.02 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Troy Wichterman, the Chief Financial Officer of BioLife Solutions, sold 987 shares of common stock on January 6, 2025.
• The shares were sold at a price of $27.02 per share.
• This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on January 3, 2023.
• The sale was to satisfy tax withholding obligations related to the vesting of restricted stock.
• Following the transaction, Wichterman directly owns 121,779 shares of BioLife Solutions common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to an insider stock sale under a pre-arranged plan. It does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 plans to manage their stock sales and avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among corporate executives to manage stock sales and comply with insider trading regulations.
• Similar filings are regularly made by executives at other publicly traded companies, such as those in the biotechnology and life sciences sectors, including companies like Thermo Fisher Scientific and Danaher Corporation.

Stakeholder Impact

• The stock sale by the CFO may have a minor impact on the stock price, but it is unlikely to be significant given the pre-arranged nature of the transaction.

Key Dates

Keywords

BioLife Solutions, BLFS, Troy Wichterman, SEC Form 4, insider trading, stock sale, Rule 10b5-1, CFO, equity securities